参考文献/References:
［1］GBD Chronic Kidney Disease Collaboration.Global,regional,and national burden of chronic kidney disease,1990-2017:a systematic analysis for the global burden of disease study 2017［J].Lancet，2020，395(10225):709-733.
［2]Lv JC,Zhang LX.Prevalence and disease burden of chronic kidney disease［J].Advances in Experimental Medicine and Biology,2019,1165:3-15.
［3]Sabatino A,Regolisti G,Brusasco I,et al.Alterations of intestinal barrier and microbiota in chronic kidney disease［J].Nephrology Dialysis Transplantation,2014,30(6):924-933.
［4]Glenwright AJ,Pothula KR,Bhamidimarri SP,et al.Structural basis for nutrient acquisition by dominant members of the human gut microbiota［J].Nature,2017,541(7637):407-411.
［5]Tropini C,Earle KA,Huang KC,et al.The gut microbiome:connecting spatial organization to function［J].Cell Host & Microbe,2017,21(4):433-442.
［6]魏丽雪,杜玄.肠道菌群与肾脏病研究新进展［J].中国中西医结合肾病杂志,2020,21(5):453-455.
［7]Anders HJ,Andersen K,Stecher B.The intestinal microbiota,a leaky gut,and abnormal immunity in kidney disease［J].Kidney International,2013,83(6):1010-1016.
［8]Simrén M,Barbara G,Flint HJ,et al.Intestinal microbiota in functional bowel disorders:a Rome foundation report［J].Gut,2013,62(1):159-176.
［9]Fujisaka S,Avila-Pacheco J,Soto M,et al.Diet,genetics,and the gut microbiome drive dynamic changes in plasma metabolites［J].Cell Reports,2018,22(11):3072-3086.
［10]Furusawa Y,Obata Y,Fukuda S,et al.Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells［J].Nature,2013,504(7480):446-450.
［11]Meijers BKI,Evenepoel P.The gut-kidney axis:indoxyl sulfate,p-cresyl sulfate and CKD progression［J].Nephrology,Dialysis,Transplantation,2011,26(3):759-761.
［12]Pahl MV,Vaziri ND.The chronic kidney disease - colonic axis［J].Seminars in Dialysis,2015,28(5):459-463.
［13]刁宗礼,刘文虎,阴赪宏.肠道菌群与慢性肾脏病的相关性［J].中国医刊,2019,54(6):595-597.
［14]包文晗,王悦.慢性肾脏病患者肠道菌群的变化及影响研究［J].中国全科医学,2018,21(24):2927-2931.
［15]韩文贝,刘莹露,万毅刚,等.慢性肾脏病肠道菌群失调的病理机制、治疗策略及中药的干预作用［J].中国中药杂志,2017,42(13):2425-2432.
［16]Koppe L,Fouque D,Soulage CO.The role of gut microbiota and diet on uremic retention solutes production in the context of chronic kidney disease［J].Toxins,2018,10(4):155.
［17]Kim SM,Song IH.The clinical impact of gut microbiota in chronic kidney disease［J].The Korean Journal of Internal Medicine,2020,35(6):1305-1316.
［18]Vanholder R,Baurmeister U,Brunet P,et al.A bench to bedside view of uremic toxins［J].Journal of the American Society of Nephrology:JASN,2008,19(5):863-870.
［19]Graboski AL,Redinbo MR.Gut-derived protein-bound uremic toxins［J].Toxins,2020,12(9):590.
［20]Ueno H,Koyama H,Fukumoto S,et al.Advanced glycation end products,carotid atherosclerosis,and circulating endothelial progenitor cells in patients with end-stage renal disease［J].Metabolism:Clinical and Experimental,2011,60(4):453-459.
［21]Lees HJ,Swann JR,Wilson ID,et al.Hippurate:the natural history of a mammalian-microbial cometabolite［J].Journal of Proteome Research,2013,12(4):1527-1546.
［22]McIntyre CW,Harrison LE,Eldehni MT,et al.Circulating endotoxemia:a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease［J].Clinical Journal of the American Society of Nephrology:CJASN,2011,6(1):133-141.
［23]Ramezani A,Raj DS.The gut microbiome,kidneydisease,and targeted interventions［J].Journal of the American Society of Nephrology,2014,25(4):657-670.
［24]Rice JB,Stoll LL,Li WG,et al.Low-level endotoxin induces potent inflammatory activation of human blood vessels:inhibition by statins［J].Arteriosclerosis,Thrombosis,and Vascular Biology,2003,23(9):1576-1582.
［25]王仡豪,郁胜强.慢性肾脏病与肠道微生态的相互影响［J].临床肾脏病杂志,2019,19(9):700-705.
［26]Ivanov II,Atarashi K,Manel N,et al.Induction of intestinal Th17 cells by segmented filamentous bacteria［J].Cell,2009,139(3):485-498.
［27]Chen YY,Chen DQ,Chen L,et al.Microbiome-metabolome reveals the contribution of gut-kidney axis on kidney disease［J].Journal of Translational Medicine,2019,17(1):5.
［28]Yang T,Richards EM,Pepine CJ,et al.The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease［J].Nature Reviews Nephrology,2018,14(7):442-456.
［29]Maynard CL,Elson CO,Hatton RD,et al.Reciprocal interactions of the intestinal microbiota and immune system［J].Nature,2012,489(7415):231-241.
［30]Johnson-Henry KC,Hagen KE,Gordonpour M,et al.Surface-layer protein extracts from Lactobacillus helveticus inhibit enterohaemorrhagic Escherichia coli O157:H7 adhesion to epithelial cells［J].Cellular Microbiology,2007,9(2):356-367.
［31]Vaziri ND,Liu SM,Lau WL,et al.High amylose resistant starch diet ameliorates oxidative stress,inflammation,and progression of chronic kidney disease［J].PLoS One,2014,9(12):e114881.
［32]Rossi M,Johnson DW,Campbell KL.The kidney-gut axis:implications for nutrition care［J].Journal of Renal Nutrition,2015,25(5):399-403.
［33]周韩菁,朱菡,姚颖.益生菌干预:慢性肾脏病治疗的新策略［J].中国医刊,2018,53(9):953-957，948.
［34]张镭,聂静.肠道菌群与慢性肾脏病［J].临床肾脏病杂志,2016,16(11):697-700.
［35]张小娟,蒋珍秀,董娜.基于肠道微生态及“肠-肾轴”理论探讨慢性肾脏病从脾论治机理［J].中国中医药信息杂志,2020,27(6):14-17.
［36]孔畅，陈东峰，赵泉霖.从肠道菌群探讨肥胖从脾论治的机理［J].中国中医基础医学杂志，2017,23(9):1214-1216.
［37]杨康,纪越,赵庆云,等.慢性肾脏病与肠道微生态的关系、治疗策略及中医药干预研究［J].中医药学报,2019,47(1):1-6.
［38]裴明,杨洪涛.从肠道微生态看中医肾病学的发展机遇［J].中华中医药杂志,2019,34(6):2336-2341.
［39]李玉丽,肖嫩群,谭周进.代谢性疾病的肠道菌群相关研究进展［J].世界华人消化杂志,2020,28(23):1192-1199.
［40]邹秋萍,李婷,李艳平.中药及活性成分通过影响肠道菌群干预结直肠癌的研究进展［J].国际药学研究杂志,2020,47(12):1027-1032.
［41]姚东升,叶朝阳.基于“肠-肾轴”中医药治疗慢性肾脏病的研究进展［J].内蒙古中医药,2020,39(12):159-160.
［42]Xu J,Chen HB,Li SL.Understanding the molecular mechanisms of the interplay between herbal medicines and gut microbiota［J].Medicinal Research Reviews,2017,37(5):1140-1185.
［43]樊均明,马欣,文集.肠道菌群的微生态改变与慢性肾脏疾病［J].中国中西医结合肾病杂志,2013,14(12):1035-1037.